ADPT Adaptive Biotechnologies Corp — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

—

Period return

—

Volume

—

There isn’t enough historical data to display yet.

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 04.Highin 14 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 13.LowHOLD2 months ago
Morgan Stanley: Equal-Weight
US analyst rating / recommendation change.
2026. 05. 07.LowBUY3 months ago
JP Morgan: Overweight
US analyst rating / recommendation change.
2026. 05. 07.LowBUY3 months ago
TD Cowen: Buy
US analyst rating / recommendation change.
2026. 05. 06.LowBUY3 months ago
Guggenheim: Buy
US analyst rating / recommendation change.
2026. 05. 06.LowBUY3 months ago
BTIG: Buy
US analyst rating / recommendation change.
2026. 02. 07.LowBUY6 months ago
JP Morgan: Overweight
US analyst rating / recommendation change.
2026. 02. 06.LowBUY6 months ago
BTIG: Buy
US analyst rating / recommendation change.
2026. 01. 27.LowBUY6 months ago
Guggenheim: Buy
US analyst rating / recommendation change.
2025. 11. 12.LowHOLD8 months ago
Morgan Stanley: Equal-Weight
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $20.14 · 7 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Sector: Healthcare
Industry: Diagnostics & Research
HQ: Seattle, WA, United States
Fiscal year end: —
Employees: 624
IPO date: —

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 04.	After market close (AMC)	$-0.14	—	—	$65.69M	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$-0.2	—	—	$52.44M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-0.86	—	—	$131.5M	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-0.64	—	—	$85.06M	Reported

Adaptive Biotechnologies Corp

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 13.	Morgan Stanley	—	Maintain	Equal-Weight → Equal-Weight	—	Morgan Stanley: Equal-Weight
2026. 05. 07.	JP Morgan	—	Maintain	Overweight → Overweight	—	JP Morgan: Overweight
2026. 05. 07.	TD Cowen	—	Maintain	Buy → Buy	—	TD Cowen: Buy
2026. 05. 06.	Guggenheim	—	Maintain	Buy → Buy	—	Guggenheim: Buy
2026. 05. 06.	BTIG	—	Maintain	Buy → Buy	—	BTIG: Buy
2026. 02. 07.	JP Morgan	—	Maintain	Overweight → Overweight	—	JP Morgan: Overweight